Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500
Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 Pipeline Review, H2 2017
Summary
According to the recently published report 'Nociceptin Receptor Pipeline Review, H2 2017'; Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappatype3 opioid receptor is a protein encoded by the OPRL1 opioid receptorlike 1 gene. NOP receptors are located both pre and postsynaptically in various areas of CNS. The nociceptin receptor NOP and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.
The report 'Nociceptin Receptor Pipeline Review, H2 2017' outlays comprehensive information on the Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Immunology which include indications Neuropathic Pain, Dyskinesia, Inflammatory Pain, Substance Drug Abuse, Acute Pain, Chronic Pain, Pain, Alcohol Addiction, Bladder Pain, Cancer Pain, Diabetic Neuropathic Pain, Drug Addiction, Hypersensitivity, Low Back Pain, Major Depressive Disorder, Osteoarthritis Pain, PostTraumatic Stress Disorder PTSD, Postherpetic Neuralgia, Pulmonary Arterial Hypertension, Systolic Hypertension and Visceral Pain.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1
The report reviews Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 targeted therapeutics and enlists all their major and minor projects
The report assesses Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Nociceptin Receptor Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
